|
Match
|
Document |
Document Title |
|
|
US20090281091 |
METHODS FOR MODULATING BLADDER FUNCTION
This invention provides methods and pharmaceutical compositions for modulating bladder function, and in particular for maintaining bladder control or treating urinary incontinence.
|
|
|
US20090281090 |
BIOMARKERS FOR THE PREDICTION OF RESPONSIVENESS TO CLOZAPINE TREATMENT
This invention provides methods to predict the likelihood of suicidal or self-destructive behaviour in a patient during treatment. The method employs the detection of a VNTR polymorphism in the...
|
|
|
US20090280176 |
CONTROLLED RELEASE FORMULATIONS OF ALPRAZOLAM
A controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile, is provided.
|
|
|
US20090270373 |
TREATMENT OF DOWN SYNDROM WITH BENZODIAZEPINE RECEPTOR ANTAGONISTS
Pharmaceutical compositions and methods of treating Down Syndrome, mental retardation or both are provided. The pharmaceutical compositions comprise one or more benzodiazepine receptor antagonists,...
|
|
|
US20090258863 |
Method for treatment of amyotrophic lateral sclerosis using talampanel
A method of treating a human patient afflicted with amyotrophic lateral sclerosis (ALS) comprising periodically administering to the human patient for a therapeutically effective duration a...
|
|
|
US20090246145 |
Imaging Correlates of Neurogenesis With MRI
This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises...
|
|
|
US20090239849 |
Aryl-Fused Spirocyclic Compounds
The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal...
|
|
|
US20090239840 |
AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for...
|
|
|
US20090233912 |
NON-AQUEOUS PHARMACEUTICAL COMPOSITION
A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from...
|
|
|
US20090227568 |
METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT
The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of...
|
|
|
US20090227565 |
Biphenyl Vasopressin Agonists
A compound of the formulae (I) or (II):
wherein:
Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1;
represents:
(1) a...
|
|
|
US20090226522 |
PROCESS TO MINIMIZE POLYMORPHISM
The commercial formulation of fast dispersing dosage forms (FDDF) requires substantial holding times during which large quantities of pharmaceutically active substance are formed into individual...
|
|
|
US20090221560 |
Pharmaceutical Formulation
This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, one or more suitable...
|
|
|
US20090221559 |
BENZODIAZEPINES AS HCV INHIBITORS
The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In...
|
|
|
US20090221535 |
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , T, U, V, W, X, Y, Z. R 4 , R 5a ?, R 5b , R 5c , R 6 , m and n are defined...
|
|
|
US20090215751 |
Use of Selective Chloride Channel Modulators to Treat Alcohol and/or Stimulant Substance Abuse
The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABA A chloride channel...
|
|
|
US20090209525 |
ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY
A method developed to identify receptor modulators, involving providing a mutant receptor, wherein said mutant receptor has a mutation that alters the activity of said mutant receptor compared to a...
|
|
|
US20090209480 |
CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous...
|
|
|
US20090203720 |
Methods for inhibiting cell growth
Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1α. A cell or a tissue can be screened for enhanced susceptibility...
|
|
|
US20090202604 |
Benzodiazepine Formulation in a Polyorthoester Carrier
Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an...
|
|
|
US20090198145 |
COMPOSITIONS, METHODS, AND SYSTEMS FOR RAPID INDUCTION AND MAINTENANCE OF CONTINUOUS REM SLEEP
Compositions, kits, methods, and systems to induce, maintain, monitor, and interpret a continuous, un-fragmented REM sleep state in humans, generate dreams, recover sleep, create brain neuronal...
|
|
|
US20090196824 |
TREATMENT OF SEQUELAE OF PSYCHIATRIC DISORDERS
In general, the invention provides methods and compositions for treating sequela of weight gain or pain insensitivity, e.g., in a subject suffering from a psychiatric disorder, such as...
|
|
|
US20090186879 |
TRICYCLIC COMPOUNDS AND USE THEREOF
There is provided a compound of the formula (I′):
wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R 1 is an optionally substituted hydrocarbon group, etc., R 2 is an optionally...
|
|
|
US20090186878 |
CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms...
|
|
|
US20090170837 |
METHODS FOR TREATING RAS DRIVEN CANCER IN A SUBJECT
The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the...
|
|
|
US20090163451 |
METHODS FOR TREATING VISCERAL PAIN
The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT 1B or 5HT 1D receptor agonist, (e.g., a triptan). These methods can be used, for...
|
|
|
US20090156583 |
Tricyclic Amide Derivatives
The present invention relates to compounds of formula I
wherein A, G, r and R 1 to R 5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The...
|
|
|
US20090156578 |
3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or...
|
|
|
US20090156562 |
NOVEL COLORED SOLUTIONS OF INJECTABLE DRUGS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected...
|
|
|
US20090155331 |
INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS
Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable...
|
|
|
US20090143356 |
Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity
Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent.
(wherein
...
|
|
|
US20090137564 |
5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents
The present invention relates to compounds of formula I,
processes for their production and their use as anti-inflammatory agents.
|
|
|
US20090137563 |
PROCESS FOR THE PREPARTION OF OLANZAPINE
The invention relates to a process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno-[2,3-b][1,5]b
enzodiazepine (olanzapine) of the formula (I) by reacting...
|
|
|
US20090131363 |
Deuterated darunavir
This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel...
|
|
|
US20090130216 |
MULTIMODAL PARTICULATE FORMULATIONS
Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.
|
|
|
US20090124607 |
Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases
Compounds of formula (I): or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the...
|
|
|
US20090124606 |
Composition for Treatment of Psychosis
New pharmaceutical combination providing to decrease or eliminate the extrapyramidal side effects of antipsychotic active ingredients by combination of deramciclane with a classic antipsychotic...
|
|
|
US20090105228 |
Heterocyclic benzodiazepine cgrp receptor antagonists
Compounds of formula I:
(where variables R 2 , R 7 , D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of...
|
|
|
US20090105187 |
METHODS OF TREATING LENTIVIRUS INFECTION
The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a...
|
|
|
US20090093466 |
Carboxamide GABAa ALPHA2 Modulators
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
|
|
|
US20090069306 |
PROCESS FOR PRODUCING HIGHLY PURE MIDAZOLAM AND SALTS THEREOF
Provided is a process for producing highly pure midazolam and salts thereof, and a pharmaceutical composition containing the highly pure midazolam and/or a salt thereof.
|
|
|
US20090069267 |
CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous...
|
|
|
US20090062262 |
NON STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS
The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof. In this formula R 1 is H or (1-4C)alkyl; R 2 is —C(O)R 15 or —S(O)2R 15 ;...
|
|
|
US20090060871 |
ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS
A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby...
|
|
|
US20090054412 |
Treatment of Sleep Disorders
A method for treating various types of insomnia is provided using 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5me
thyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its...
|
|
|
US20090054399 |
HIV INTEGRASE INHIBITORS
Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R 1 , R 2 and R 3 are defined herein. The compounds are useful for...
|
|
|
US20090048234 |
Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents,...
|
|
|
US20090042861 |
Prophylactic or Therapeutic Agent for Depression or Anxiety Disorder
The present invention provides a prophylactic or therapeutic agent for depression or anxiety disorders, comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethy
l]propionamide.
|
|
|
US20090036431 |
Cytotoxic Agents Comprising New Tomaymycin Derivatives
The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.
|
|
|
US20090029967 |
ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS
There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the...
|